Overall survival in AML ≤ 60 years, based on the ECOG randomized study (E1900) of anthracycline dose in induction.
 A. All patients on study
 B. Favorable and intermediate cytogenetics
 C. Unfavorable cytogenetics
 Reproduced with permission from Fernandez HF, Sun Z, Yao X, et al. Anthracycline dose intensification in acute myeloid leukemia. N Engl J Med. 2009;361:1249–1259.